Commercial Validation Accelerates

The most likely path is that the result is treated as a meaningful proof point for autonomous AI-driven protein engineering, but not yet a drug-discovery revolution. Large pharma and biotech partners begin limited pilots with Anthropic-style wet-lab agents focused on binders, enzymes, and assay design.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.